Results 91 to 100 of about 12,272 (191)

Mechanistic Study of Platelet Membrane‐Coated Resveratrol Nanosystem in Mitochondrial Dysfunction and Endothelial Senescence During Atherosclerotic Lesion Development via FOXM1 Activation

Aging Cell, Volume 25, Issue 8, August 2026.
Schematic diagram of the mechanism by which PM@RSV NPs alleviate AS via FOXM1 activation. ABSTRACT Atherosclerosis (AS) is closely linked to endothelial cell (EC) senescence and mitochondrial dysfunction, which impair vascular repair. Resveratrol (RSV) has antioxidant, anti‐inflammatory, and pro‐angiogenic effects, but its clinical use is restricted by
Li Xiao, Zexin Zhan, Ping Liu, Bing Qin
wiley   +1 more source

PCSK9 inhibitor failure in a statin-intolerant FH patient with a novel LDLR variant: a case report

Frontiers in Cardiovascular Medicine
BackgroundApproximately 3.8 million patients in China suffer from familial hypercholesterolemia (FH). Statins and PCSK9 inhibitors are recommended by guidelines as therapeutic agents.
Yuan Li, Huiyan Jiang, Yajuan Xiong, Simin Yan, Xin Chen   +4 more
doaj   +1 more source

Multivalent antibody‐based conjugates as new tools for tailored modulation of G protein–coupled receptors

British Journal of Pharmacology, Volume 183, Issue 16, Page 4512-4531, August 2026.
The G protein–coupled receptor (GPCR) superfamily consists of the most common targets of approved drugs. Targeting GPCRs offers appealing avenues for therapeutic development. Antibodies and their fragments, such as single‐domain antibodies (VHHs or nanobodies), have emerged as useful alternatives to small molecule pharmacophores as building blocks in ...
Shivani Sachdev, Ross W. Cheloha
wiley   +1 more source

PCSK9 Inhibitors

Journal of the American College of Cardiology, 2017
Mark A. Hlatky, Dhruv S. Kazi
openaire   +2 more sources

Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders

Vascular Health and Risk Management, 2016
Sanjiv Gupta Department of Interventional Cardiology, Santokba Durlabhji Memorial Hospital Cum Medical Research Institute, Jaipur, India Abstract: The aim of this manuscript is to review available data to evaluate the present status of proprotein ...
Gupta S
doaj  

Jiuwei Xiaozhi Decoction Alleviates High‐Fat Diet‐Induced MASLD by Suppressing Hepatic SREBP2‐Driven Cholesterogenesis and Restoring PPARα‐Mediated Fatty Acid Oxidation

Chemical Biology &Drug Design, Volume 108, Issue 2, August 2026.
Studies have found that Jiuwei Xiaozhi Decoction can improve high‐fat diet‐induced fatty liver disease, mainly by regulating the SREBP2 and PPARα pathways to balance hepatic lipid metabolism while reducing inflammatory responses. ABSTRACT Jiuwei Xiaozhi Decoction (JWXZ) is a nine‐herb traditional Chinese medicine formula clinically used for hepatic ...
Youcheng Ma, Xinrui Gao, Ji Wang, Lingru Li, Zhen Huang, Fangli Li   +5 more
wiley   +1 more source

Comparative Effects of Emerging Lp(a)‐Lowering Agents and PCSK9‐Directed Therapies on Lipoprotein(a): A Network Meta‐Analysis of Randomised Clinical Trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7403-7415, August 2026.
ABSTRACT Aims Elevated lipoprotein(a) [Lp(a)] is a genetic ASCVD risk factor that often persists despite intensive LDL‐C lowering. We compared the efficacy and safety of emerging Lp(a)‐targeted therapies (siRNAs, antisense oligonucleotides and an oral assembly inhibitor) with PCSK9‐directed therapies.
Jihad Abu Zayed, Nada A. Al‐Awamleh, Mahmoud Hamad, Mohammad Ibrahim Mahmoud Hdaib, Hazem Ayesh   +4 more
wiley   +1 more source

Contemporary Management of Aortic Stenosis: Timing of Intervention and Lifetime Valve Management

European Journal of Clinical Investigation, Volume 56, Issue 8, August 2026.
As transcatheter treatment expands to younger and lower‐risk patients, aortic stenosis management is evolving from a single procedure to lifelong valve care. This review highlights the key challenges across the patient journey, from timely diagnosis and optimal intervention to durable valve performance, long‐term surveillance, and repeat intervention ...
Ottavia Cozzi, Thomas Pilgrim
wiley   +1 more source

Oral PCSK9 inhibitors for elevated LDL-C: A systematic review and meta-analysis of randomized trials

American Journal of Preventive Cardiology
Background: Injectable proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are an established strategy to lower low-density lipoprotein cholesterol (LDL-C) and reduce atherosclerotic cardiovascular disease risk. Recently developed oral PCSK9
Aditya Karthikeyan, Avrohom Karp, Maisha Maliha, Amrin Kharawala, Sridhar Mangalesh, Priyansh Shah, Vishakha Modak, Adir Alper, Apoorva Doshi, Hamsa Murli, Vikyath Satish, Kuan-Yu Chi, Robert T. Faillace   +12 more
doaj   +1 more source

The changing epidemiology of human type 2 diabetes–associated atherosclerosis: Pathophysiological mechanisms and emerging treatment possibilities

Journal of Internal Medicine, Volume 300, Issue 2, Page 131-152, August 2026.
Abstract Type 2 diabetes (T2D) is a major global health concern strongly associated with atherosclerosis and subsequent macrovascular complications. These complications are the leading cause of death among T2D patients. Despite a decline in cardiovascular events over the last decade, individuals with T2D still have an approximately doubled risk ...
Dania Al‐Sharify, Jiangming Sun, Andreas Edsfeldt   +2 more
wiley   +1 more source